Available experimental evidence suggests a role for high-density lipoprotein cholesterol
(HDL-C) in incident chronic kidney disease (CKD) and its progression. However, clinical …

Background High‐density lipoprotein cholesterol (HDL‐C) levels are generally decreased in
patients with chronic kidney disease (CKD). However, studies on the relationship between …

Emerging epidemiological evidence indicates that low serum high-density lipoprotein
cholesterol (HDL-C) levels are associated with the risk of progression of chronic kidney …

Highlights•A total of 3% participants developed new-onset CKD during 2.8 years follow-
up.•NonHDLc/HDLc is associated with a greater risk of the new-onset CKD.•The risk of CKD …

In the general population, HDL cholesterol (HDL-C) is associated with reduced
cardiovascular events. However, recent experimental data suggest that the vascular effects …

Background Increased total cholesterol (TC), triglycerides (TG), low-density lipoprotein
cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) …

Results The incidence rates of MI, CI, and CB were 1.43, 2.53, and 1.01 per 100 person-
years, and death rates after these events were 0.23, 0.21, and 0.29 per 100 person-years …

Rationale & Objective A large residual risk for atherosclerotic cardiovascular disease
(ASCVD) remains in the setting of chronic kidney disease (CKD) despite treatment with …

Although reducing low-density lipoprotein-cholesterol (LDL-C) levels with lipid-lowering
agents (statins) decreases cardiovascular disease (CVD) risk, a substantial residual risk (up …

Background The impact of the triglycerides to high-density lipoprotein cholesterol (TG: HDL-
C) ratio on chronic kidney disease (CKD) is unclear. Study Design Longitudinal cohort study …